UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): August 21, 2007
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
0-22705
|
|
33-0525145 |
(State or other
jurisdiction of
incorporation or
organization)
|
|
(Commission File
Number)
|
|
(IRS Employer Identification
No.) |
| |
|
|
| 12790 El Camino Real
|
|
92130 |
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (858) 617-7600
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2 (b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4 (c))
TABLE OF CONTENTS
ITEM 8.01 OTHER EVENTS.
On August 21, 2007 Neurocrine Biosciences, Inc. announced that the U.S. Food and Drug
Administration had accepted its resubmission of its new drug application for indiplon 5 mg and 10
mg capsules and has set a PDUFA action date of December 12, 2007.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) EXHIBITS.
| |
|
|
| Exhibit |
|
|
| Number |
|
Description of Exhibit |
99.1
|
|
Press Release dated August 21, 2007 |